Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
WALTHAM, Mass., Feb. 6, 2013 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) announced today that Lonnie Moulder, Chief Executive Officer, and Mary Lynne Hedley, Ph.D., President and Chief Scientific...
-
WALTHAM, Mass., Nov. 29, 2012 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) announced today that Lonnie Moulder, Chief Executive Officer, and Mary Lynne Hedley, Ph.D., President and Chief Scientific...
-
WALTHAM, Mass., Nov. 1, 2012 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) announced today that the first clinical trial of its proprietary Anaplastic Lymphoma Kinase (ALK) inhibitor, TSR-011, has...
-
Continued Enrollment for the Global Registration Program for Rolapitant Announced Clearance of Investigational New Drug Application for TSR-011 Appointed Robert E. Martell, M.D., Ph.D.,...
-
WALTHAM, Mass., Oct. 16, 2012 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) will announce its third quarter 2012 financial results on Thursday, October 25th, 2012, after the close of the U.S....
-
WALTHAM, Mass., Oct. 2, 2012 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) announced today that the Investigational New Drug (IND) application for TSR-011, an orally available ALK inhibitor (targeted...
-
WALTHAM, Mass., Sept. 4, 2012 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) today announced the appointment of Dr. Robert Martell as Chief Medical Officer. Dr. Martell is a practicing medical...
-
WALTHAM, Mass., Sept. 4, 2012 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) announced today that Lonnie Moulder, Chief Executive Officer, and Mary Lynne Hedley, Ph.D., President and Chief Scientific...
-
WALTHAM, Mass., Aug. 29, 2012 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) today announced that Lonnie Moulder, Chief Executive Officer, will be presenting at the Robert W. Baird 2012 Healthcare...
-
Key Rolapitant Clinical Trial Results Presented at ASCO and MASCC Meetings In-Licensed Niraparib, a Potentially First and Best-in-Class PARP Inhibitor Raised Over $86.8 Million in Gross...